DECIPHERA PHARMACEUTICALS, INC. Financials Deciphera Pharmaceuticals, Inc.
Equities
DCPH
US24344T1016
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.59 USD | +0.08% |
|
+0.16% | +58.65% |
| Jun. 11 | Ono Pharmaceutical Closes Deciphera Deal for About $2.4 Billion | DJ |
| Jun. 11 | Deciphera Pharmaceuticals, Inc. Announces Board and Committee Changes | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,177 | 3,249 | 571.4 | 1,108 | 1,292 | 2,213 | - | - |
| Enterprise Value (EV) 1 | 2,597 | 2,697 | 484.3 | 1,043 | 1,212 | 2,213 | 2,213 | 2,213 |
| P/E ratio | -13.9 x | -11.9 x | -1.89 x | -6.92 x | -7.04 x | -13.7 x | -14.5 x | -23.7 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 127 x | 77.2 x | 5.94 x | 8.26 x | 7.91 x | 10.9 x | 8.86 x | 6.77 x |
| EV / Revenue | 127 x | 77.2 x | 5.94 x | 8.26 x | 7.91 x | 10.9 x | 8.86 x | 6.77 x |
| EV / EBITDA | -15,893,127 x | -12,083,939 x | -1,923,355 x | -6,160,841 x | -6,187,870 x | - | - | - |
| EV / FCF | -20.6 x | -13.3 x | -2.35 x | -7.21 x | -8.76 x | -12.6 x | -15.2 x | -45.1 x |
| FCF Yield | -4.85% | -7.54% | -42.5% | -13.9% | -11.4% | -7.94% | -6.56% | -2.22% |
| Price to Book | 5.88 x | 6.05 x | 1.88 x | 3.62 x | 3.7 x | 10.1 x | 8.34 x | 12.7 x |
| Nbr of stocks (in thousands) | 51,044 | 56,933 | 58,481 | 67,576 | 80,123 | 86,476 | - | - |
| Reference price 2 | 62.24 | 57.07 | 9.770 | 16.39 | 16.13 | 25.59 | 25.59 | 25.59 |
| Announcement Date | 3/9/20 | 2/9/21 | 2/8/22 | 2/7/23 | 2/6/24 | - | - | - |
1USD in Million2
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 25 | 42.09 | 96.15 | 134 | 163.4 | 202.4 | 249.6 | 326.8 |
| EBITDA | -199.9 | -268.9 | -297.1 | -179.8 | -208.9 | - | - | - |
| EBIT 1 | -200.7 | -271.2 | -300.1 | -182.7 | -211 | -177.2 | -171 | -110.9 |
| Operating Margin | -802.9% | -644.36% | -312.1% | -136.32% | -129.14% | -87.53% | -68.5% | -33.95% |
| Earnings before Tax (EBT) 1 | -192.3 | -266.5 | -300 | -178.2 | -194.5 | -164.5 | -153.5 | -92.36 |
| Net income 1 | -192.3 | -266.5 | -300 | -178.9 | -194.9 | -164.5 | -165.5 | -104.1 |
| Net margin | -769.02% | -633.19% | -311.98% | -133.49% | -119.34% | -81.25% | -66.3% | -31.86% |
| EPS 2 | -4.480 | -4.780 | -5.160 | -2.370 | -2.290 | -1.870 | -1.762 | -1.080 |
| Free Cash Flow 1 | -154.2 | -245 | -242.8 | -153.7 | -147.5 | -175.6 | -145.2 | -49.05 |
| FCF margin | -616.92% | -582.13% | -252.52% | -114.67% | -90.28% | -86.76% | -58.17% | -15.01% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/9/20 | 2/9/21 | 2/8/22 | 2/7/23 | 2/6/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 580 | 552 | 87.1 | 64.7 | 80 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -154 | -245 | -243 | -154 | -147 | -176 | -145 | -49.1 |
| ROE (net income / shareholders' equity) | -46.5% | -48.9% | -70.7% | -55.4% | -56.3% | -84% | -52% | -55% |
| ROA (Net income/ Total Assets) | -41% | -42.1% | -56% | -40.5% | -42% | - | - | - |
| Assets 1 | 469 | 632.4 | 536 | 441.8 | 463.8 | - | - | - |
| Book Value Per Share 2 | 10.60 | 9.440 | 5.200 | 4.530 | 4.360 | 2.530 | 3.070 | 2.020 |
| Cash Flow per Share | -3.480 | - | - | - | - | - | - | - |
| Capex 1 | 4.94 | 5.32 | 1.97 | 0.84 | 0.78 | 2.43 | 2.97 | 3.52 |
| Capex / Sales | 19.74% | 12.63% | 2.05% | 0.63% | 0.48% | 1.2% | 1.19% | 1.08% |
| Announcement Date | 3/9/20 | 2/9/21 | 2/8/22 | 2/7/23 | 2/6/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
| 1st Jan change | Capi. | |
|---|---|---|
| +58.65% | 2.21B | |
| +17.73% | 124B | |
| +16.88% | 111B | |
| -9.04% | 23.17B | |
| +4.40% | 22.94B | |
| -38.15% | 17.42B | |
| -7.75% | 17.42B | |
| -15.36% | 16.9B | |
| +3.42% | 13.71B | |
| +29.63% | 11.82B |
- Stock Market
- Equities
- DCPH Stock
- Financials Deciphera Pharmaceuticals, Inc.
